Opportunities Preloader

Please Wait.....

Report

Global Diabetes Drugs Market Report and Forecast 2023-2031

Market Report I 2023-05-02 I 147 Pages I EMR Inc.

Global Diabetes Drugs Market Report and Forecast 2023-2031
Global Diabetes Drugs Market Outlook
The global diabetes drugs market value was USD 70.7 billion in 2022, driven by the increasing prevalence of diabetes across the globe. The market is anticipated to grow at a CAGR of 5.3% during the forecast period of 2023-2031 to achieve a value of USD 112.6 billion by 2031.

Diabetes Drugs Introduction
Diabetes drugs are medications used to lower blood sugar levels in individuals with diabetes. These drugs help manage diabetes by either increasing insulin production or sensitivity, inhibiting the absorption of carbohydrates in the intestines, or slowing down the release of glucose from the liver.
The diabetes drugs market is primarily driven by the increasing prevalence of diabetes globally. The rise in the number of diabetic patients has led to a surge in the demand for diabetes drugs. Additionally, the growing awareness about diabetes management and the availability of advanced diabetes drugs are also fueling market growth.
Moreover, the introduction of technologically advanced products such as insulin pumps and continuous glucose monitoring systems has transformed the way diabetes is managed, further boosting the demand for diabetes drugs. On the other hand, patent expiration and the resultant entry of generic drugs into the market pose a significant challenge to market growth.
Overall, the diabetes drugs market is expected to witness continued growth in the coming years, driven by increasing patient awareness, rising healthcare expenditure, and ongoing R&D efforts to develop innovative diabetes drugs.
Diabetes Drugs Market Scenario
The global diabetes drugs market is a rapidly growing segment within the overall pharmaceutical industry. Diabetes is a chronic disease that affects millions of people worldwide, and the demand for effective treatments has been increasing steadily over the years. Diabetes drugs are used to regulate blood sugar levels in patients with type 1 and type 2 diabetes.
The market for diabetes drugs is driven by several factors, including an increase in the prevalence of diabetes worldwide, the rise in healthcare expenditure, and the availability of new drugs with improved efficacy and safety profiles. The market is also influenced by the increasing adoption of innovative drug delivery systems and the growing demand for personalized diabetes management solutions.
The diabetes drugs market is highly competitive, with several major players competing for market share. Companies in this space are focusing on developing novel drugs and improving existing treatments to meet the evolving needs of patients.
Overall, the diabetes drugs market is expected to continue to grow at a significant rate in the coming years, driven by the increasing demand for effective diabetes treatments and the development of new and innovative drugs.
Diabetes Drugs Market Segmentations
Market Breakup by Drugs
- Oral Anti-diabetic Drugs
- Alpha-glucosidase Inhibitor
- Biguanides
- Bile Acid Sequestrants
- Dopamine-2 Agonists
- DPP-4 Inhibitors
- Meglitinides
- SLGT2 Inhibitors
- Sulfonylureas
- TZDs
- Oral Combination Therapy
- Insulin
- Insulin Glargine
- Insulin Aspart
- Human Insulin
- Biosimilar Insulin

Market Breakup by Diabetes Type
- Type I
- Type II

Market Breakup by Distribution Channel
- Online
- Hospital
- Retail Pharmacies

Market Breakup by End User
- Hospital
- Clinics
- Personal Use
- Other

Market Breakup by Region

- North America
- United States of America
- Canada

- Europe
- United Kingdom
- Germany
- France
- Italy
- Others

- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Key Trends in the Diabetes Drugs Market
Some key trends in the diabetes drugs market are:
- Increasing prevalence of diabetes: The increasing prevalence of diabetes worldwide is driving the growth of the diabetes drugs market. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is expected to rise to 700 million by 2045.
- Rising adoption of insulin analogs: The adoption of insulin analogs is increasing as they offer several advantages over traditional insulin such as more predictable action, fewer side effects, and improved glycemic control. The demand for insulin analogs is expected to grow in the coming years
- Development of combination therapies: The development of combination therapies that offer better glycemic control with fewer side effects is another key trend in the diabetes drugs market. Several pharmaceutical companies are focusing on developing combination therapies to improve treatment outcomes for patients.
- Increasing focus on patient-centric care: There is an increasing focus on patient-centric care in the diabetes drugs market, with a greater emphasis on improving patient outcomes and quality of life. This has led to the development of new drugs and therapies that offer better glycemic control with fewer side effects.
- Growing investment in R&D: The increasing investment in research and development (R&D) activities by pharmaceutical companies is driving innovation in the diabetes drugs market. This is leading to the development of new drugs and therapies that offer improved treatment outcomes for patients.
Diabetes Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the xx market are as follows:
- AstraZeneca Plc.
- Sanofi-aventis Groupe
- Merck & Co., Inc.
- Eli Lilly and Company.
- Home Diagnostics Inc.
- Takeda Pharmaceutical Company Limited.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Ypsomed AG
- Eli Lilly and Company
- Ascensia Diabetes Care Holdings AG
- Dexcom, Inc.
- Sanofi-Deutschland GmbH
- Roche Products Limited





1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetes Epidemiology (2016-2031)
6 Global Diabetes Drugs Market Overview
6.1 Global Diabetes Drugs Market Historical Value (2016-2022)
6.2 Global Diabetes Drugs Market Forecast Value (2023-2031)
7 Global Diabetes Drugs Market Landscape
7.1 Diabetes Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetes Drugs: Product Landscape
7.2.1 Analysis by Drug
7.2.2 Analysis by Diabetes Type
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by End User
8 Diabetes Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Diabetes Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Diabetes Drugs Market Segmentation
11.1 Global Diabetes Drugs Market by Drugs
11.1.1 Market Overview
11.1.2 Oral Anti-diabetic Drugs
11.1.2.1 Alpha-glucosidase Inhibitor
11.1.2.2 Biguanides
11.1.2.3 Bile Acid Sequestrants
11.1.2.4 Dopamine-2 Agonists
11.1.2.5 DPP-4 Inhibitors
11.1.2.6 Meglitinides
11.1.2.7 SLGT2 Inhibitors
11.1.2.8 Sulfonylureas
11.1.2.9 TZDs
11.1.2.10 Oral Combination Therapy
11.1.3 Insulin
11.1.3.1 Insulin Glargine
11.1.3.2 Insulin Aspart
11.1.3.3 Human Insulin
11.1.3.4 Biosimilar Insulin
11.2 Global Diabetes Drugs Market by Diabetes Type
11.2.1 Market Overview
11.2.2 Type I
11.2.3 Type II
11.3 Global Diabetes Drugs Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Online Retailers
11.3.3 Hospital Pharmacies
11.3.4 Retail Pharmacies
11.4 Global Diabetes Drugs Market by End User
11.4.1 Market Overview
11.4.2 Hospital
11.4.3 Clinics
11.4.4 Personal Use
11.4.5 Other
11.5 Global Diabetes Drugs Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Diabetes Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Diabetes Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Diabetes Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Diabetes Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Diabetes Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Eli Lilly and Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AstraZeneca Plc.
23.2.1 Novo Nordisk A/S
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi-aventis Groupe
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck & Co., Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Home Diagnostics Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Takeda Pharmaceutical Company Limited.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Boehringer Ingelheim International GmbH
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Novo Nordisk A/S
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ypsomed AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ascensia Diabetes Care Holdings AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Dexcom, Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sanofi-Deutschland GmbH
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Roche Products Limited
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
24 Diabetes Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE